TY - JOUR
T1 - Muscarinic type 1 receptors mediate part of nitric oxide's vagal facilitatory effect in the isolated innervated rat right atrium
AU - Hogan, K.
AU - Markos, F.
PY - 2007/2
Y1 - 2007/2
N2 - We investigated whether vagal cardiac cholinergic facilitation by nitric oxide (NO) is mediated by cardiac muscarinic receptor subtypes in the vagally innervated rat right atrium in vitro. Experiments were carried out in the presence of atenolol (4 μM). The right vagus was stimulated at 4, 8, 16, 32 Hz; pulse duration 1 ms at 20 V for 20 s; vagal postganglionic activation was achieved using nicotine (0.1, 0.3, 0.5, 1 mM) and the effect on cardiac interval (ms) assessed. Pirenzepine (1 μM), a M1 antagonist, attenuated vagally induced increase in cardiac interval. l-Arginine (0.34 mM) superfused with pirenzepine failed to reverse this attenuation, however, l-arginine applied alone reversed the reduction vagal cardiac slowing. Similarly, sodium nitroprusside (10 μM) applied alone, and not together with pirenzepine, was able to reverse the attenuation of vagal effects caused by pirenzepine. Synthetic MT7 (1 nM) toxin, a selective M1 antagonist confirmed these results. M3 antagonism using para-fluorohexahydrosiladifenidol (p-F-HHSiD) (300 nM) and M4 antagonism with PD 102807 (200 nM) did not affect the vagally induced increase in cardiac interval. Nicotine induced increase in cardiac interval was not altered by pirenzepine. These results show that antagonism of M1 receptors on cardiac vagal preganglionic fibres reduces vagal efficacy which can be recovered by either a nitric oxide synthase substrate or a NO donor.
AB - We investigated whether vagal cardiac cholinergic facilitation by nitric oxide (NO) is mediated by cardiac muscarinic receptor subtypes in the vagally innervated rat right atrium in vitro. Experiments were carried out in the presence of atenolol (4 μM). The right vagus was stimulated at 4, 8, 16, 32 Hz; pulse duration 1 ms at 20 V for 20 s; vagal postganglionic activation was achieved using nicotine (0.1, 0.3, 0.5, 1 mM) and the effect on cardiac interval (ms) assessed. Pirenzepine (1 μM), a M1 antagonist, attenuated vagally induced increase in cardiac interval. l-Arginine (0.34 mM) superfused with pirenzepine failed to reverse this attenuation, however, l-arginine applied alone reversed the reduction vagal cardiac slowing. Similarly, sodium nitroprusside (10 μM) applied alone, and not together with pirenzepine, was able to reverse the attenuation of vagal effects caused by pirenzepine. Synthetic MT7 (1 nM) toxin, a selective M1 antagonist confirmed these results. M3 antagonism using para-fluorohexahydrosiladifenidol (p-F-HHSiD) (300 nM) and M4 antagonism with PD 102807 (200 nM) did not affect the vagally induced increase in cardiac interval. Nicotine induced increase in cardiac interval was not altered by pirenzepine. These results show that antagonism of M1 receptors on cardiac vagal preganglionic fibres reduces vagal efficacy which can be recovered by either a nitric oxide synthase substrate or a NO donor.
KW - Heart
KW - Muscarinic receptors
KW - Neuronal nitric oxide
KW - Vagus
UR - https://www.scopus.com/pages/publications/33751431818
U2 - 10.1016/j.niox.2006.05.005
DO - 10.1016/j.niox.2006.05.005
M3 - Article
C2 - 16843016
AN - SCOPUS:33751431818
SN - 1089-8603
VL - 16
SP - 110
EP - 117
JO - Nitric Oxide - Biology and Chemistry
JF - Nitric Oxide - Biology and Chemistry
IS - 1
ER -